Chemotherapy Administration - R16

This coverage article has been revised and published for notice under contract numbers: 02101 (AK), 02201 (ID), 02301(OR), 02401 (WA), 03101 (AZ), 03201 (MT), 03301 (ND), 03401 (SD), 03501 (UT) and 03601.

Effective Date: January 1, 2019
Summary of Changes: Removed coding information for 2017 dates of service, as applicable, from all tables and in information for talimogene laherparepvec (Imlygic™) and rituximab and hyaluronidase (Rituxan Hycela™). In the Non-Chemotherapy Infusions section, removed C9026 as the code to use for OPPS for vedolizumab (Entyvio®) and in the Infusion Chemotherapy section for copanlisib (Aliqopa™) changed C9030 from 7/1/18 to 7/1/17.

View the locally hosted Medicare coverage article.

  • Go to Noridian Medicare Coverage Articles webpage
    • The End User Agreement for Providers will appear if you have not recently visited the website. Select "Accept" (if necessary)
  • View locally hosted Medicare coverage article

View a complete list of Noridian coverage articles.

  • Go to Noridian Medicare Coverage Articles webpage
  • Scroll to bottom of page
  • Select state/contract link of interest from applicable Active, Future, or Retired Articles column
    • Link will redirect you to CMS MCD
  • In CMS MCD, select corresponding article title to view a comprehensive revision history for this article

Last Updated Jan 10, 2019